Allergy Therapeutics PLC: Trading Update Allergy

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
36
Allergy Therapeutics PLC: Trading Update

Porto

Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”)

 Trading update

Group’s market share continues to grow

12 July 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2018 ahead of its Preliminary Results to be announced in September.

Financials

Revenues for the year are expected to be in line with market expectations at £68.3m (2017: £64.1m). This performance represents 6.6% annual growth on a reported basis and 3.5% on a constant currency basis which reflects a strong performance during an unusually weak pollen season in 2017. The Group is continuing to gain market share within its core markets in Europe and data for the key markets for the 9 months ending 31 March 2018 showed an increase of 0.7 of a market share point 1 . Expenses are expected to be in line with market expectations due to continuing cost control.

The cash balance at the end of June 2018 was £15.5m (30 June 2017: £22.1m).

Pipeline

Following the positive Grass Phase II trial, the ongoing pipeline trials continue to progress well and timing remains in line with the Group’s strategy. The results of the pivotal Birch Phase III trial for Europe continue to be expected in Q3  2018. 

Manuel Llobet, CEO at Allergy Therapeutics , stated: “Our convenient, flexible and varied product portfolio has enabled us over the past 19 years to grow revenues at 10% compound annual growth rate.  We are pleased that we have continued to make headway in market share this year, despite a poor pollen season, and have maintained a tight control on costs in the period. Our pipeline continues to progress well, with the announcement of excellent Grass Phase II results, the publication of significant papers on the long-term effect of our product and the positive Birch Phase II Trials. We are looking forward to the results of the Birch Phase III trial, expected in Q3 2018.”

1 Market data and internal estimates for 9 months to 31 March 2018, for the core European markets in which Allergy Therapeutics operates excluding Switzerland (competitor data not available)  

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014. - ENDS -

For further information, please contact:

Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Nick Wykeman, Chief Financial Officer

Panmure Gordon +44 (0) 20 7886 2500 Freddy Crossley, Emma Earl, Corporate Finance

Consilium Strategic Communications +44 20 3709 5700 Mary-Jane Elliott / Ivar Milligan / Olivia Manser allergytherapeutics@consilium-comms.com

Stern Investor Relations, Inc. +1 212 362 1200 Christina Tartaglia christina@sternir.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m 2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 89

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 88

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 114

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 149

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 108

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 128

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 125

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 36

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 117

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Current Trends in Short Interest Impacting PayPal Stock

Updated Category News Views 262

Understanding PayPal Holdings Inc and Its Market Position PayPal Holdings Inc (NYSE: PYPL) remains a prominent player in the digital payments space, continuing to see fluctuations in its market sentiment. Recently, the company has noted a significant increase in short interest as a percentage of float, climbing by 11.57%. This rise has brought the total number of shares...

Continue Reading
WillScot Plans Upcoming Earnings Call and Webcast for Q1

Updated Category News Views 152

WillScot Holdings Corporation to Share Q1 Results WillScot Holdings Corporation, a renowned leader in providing innovative temporary flexible space solutions, has announced its schedule for releasing the financial results for the first quarter of 2025. This eagerly anticipated announcement is set to take place on May 1, 2025, after market close, allowing investors and...

Continue Reading
Denarius' Bold Move: Debentures Target Early Exit

Updated Category News Views 53

Treading Against Debentures: Denarius' Maneuver Denarius Metals Corp. doesn't seem keen on playing it safe with convertible debentures tying up its business. Jaw-dropping numbers in news like this make you stop and wonder: Is this strategy brilliance, or just a roll of the dice? Time-Pressured Decisions Denarius Metals, trading as OTCQX: DNRSF, has kicked off a whirlwind...

Continue Reading
Katten Partners Recognized Among Top Experts in Crypto Sector

Updated Category News Views 185

Katten Partners Shine in Crypto Industry Recognition Katten, a well-respected law firm, has gained significant attention for its leadership in the evolving digital asset landscape. Three of its distinguished partners have been recognized by Citywealth, a leading publication in the private wealth sector, for their exceptional contributions to the cryptocurrency domain. The...

Continue Reading
Anticipating Logitech International's Earnings Success

Updated Category News Views 160

Anticipating Logitech International's Earnings Success Logitech International (NASDAQ: LOGI) is gearing up for its next quarterly earnings announcement, and investors are keenly observing potential developments. As the company prepares to report earnings, expectations are high for positive news regarding financial forecasts and results. Analyst Predictions for Earnings...

Continue Reading